Lexeo Therapeutics, Inc. cotiza a 3.04 USD y tiene una capitalización bursátil de $250M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX20…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.30 | $-0.25 | $-0.27 | $-0.33 |
| Estimado | $-0.28 | $-0.30 | $-0.30 | $-0.46 |
| Sorpresa | -7.1% | +16.7% | +10.0% | +28.3% |
| Métrica | LXEO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -40.5% | -40.4% | -0.1% |
| ROA | -37.2% | -32.0% | -5.2% |
| Current Ratio | 11.21 | 2.84 | +8.37 |
| Debt / Equity | — | 0.28 | — |